2022 World Conference on Lung Cancer (ePosters)-EP16.01-005. Cilia-related mRNA Profile Predicts Clinical Response to PD-1 Blockade in Lung Adenocarcinoma

EP16.01-005. Cilia-related mRNA Profile Predicts Clinical Response to PD-1 Blockade in Lung Adenocarcinoma

Pdf Summary

The document discusses a study conducted to develop a biomarker that can predict the response to immunotherapy in lung adenocarcinoma (LUAD) patients. The researchers focused on the role of cilia-related mRNA profiles in predicting the clinical efficacy of immunotherapy. They analyzed the expression profiles of 45 LUAD patients and divided them into a discovery cohort and a validation cohort. The patients with durable clinical benefit (DCB) were compared to those with non-durable benefit (NDB) in the discovery cohort. The researchers constructed a cilia risk model and evaluated its performance using ROC-AUC.<br /><br />The results showed that patients with lower scores in both the discovery and training cohort had a long-term clinical benefit. The cilia risk model outperformed previously reported gene expression profiles in predicting the efficacy of immunotherapy. Immune cells and immune-related pathways were significantly upregulated in the low-risk score group.<br /><br />The researchers concluded that the cilia risk model can effectively predict the response to immunotherapy in LUAD patients. This is important because immunotherapy does not work for all patients, and developing appropriate biomarkers can maximize its clinical efficacy. The study provides new insights into the role of cilia-related mRNA profiles in predicting the clinical response to immunotherapy in LUAD patients.

Asset Subtitle

Guanghui Gao

Meta Tag

Speaker Guanghui Gao

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

biomarker

immunotherapy

lung adenocarcinoma

cilia-related mRNA profiles

clinical efficacy

durable clinical benefit

cilia risk model

gene expression profiles

immune cells

response prediction